Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records
JAMA Network Open · 23.07.2024 · 7 (7) · e2421724
DOI: 10.1001/jamanetworkopen.2024.21724 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 23.07.2024. Verfasst von Angela M Thompson-Paul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control an…. Hauptthemen laut MEDLINE: Electronic Health Records, Mass Screening. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Universal screening to identify unfavorable lipid levels is recommended for US children aged 9 to 11 years and adolescents aged 17 to 21 years (hereafter, young adults ); however, screening benefits in these individuals have been questioned. Current use of lipid screening and prevalence of elevated lipid measurements among US youths is not well understood.
Objective
To investigate the prevalence of ambulatory pediatric lipid screening and elevated or abnormal lipid measurements among US screened youths by patient characteristic and test type. Design, Setting, and Participants This cross-sectional study used data from the IQVIA Ambulatory Electronic Medical Record database and included youths aged 9 to 21 years with 1 or more valid measurement of height and weight during the observation period (2018-2021). Body mass index (BMI) was calculated and categorized using standard pediatric BMI percentiles (9-19 years) and adult BMI categories (≥20 years). The data were analyzed from October 6, 2022, to January 18, 2023. Main Outcomes and Measures Lipid measurements were defined as abnormal if 1 or more of the following test results was identified: total cholesterol (≥200 mg/dL), low-density lipoprotein cholesterol (≥130 mg/dL), very low-density lipoprotein cholesterol (≥31 mg/dL), non–high-density lipoprotein cholesterol (≥145 mg/dL), and triglycerides (≥100 mg/dL for children aged 9 years or ≥130 mg/dL for patients aged 10-21 years). After adjustment for age group, sex, race and ethnicity, and BMI category, adjusted prevalence ratios (aPRs) and 95% CIs were calculated.
Results
Among 3 226 002 youths (23.9% aged 9-11 years, 34.8% aged 12-16 years, and 41.3% aged 17-21 years; 1 723 292 females [53.4%]; 60.0% White patients, 9.5% Black patients, and 2.4% Asian patients), 11.3% had 1 or more documented lipid screening tests. The frequency of lipid screening increased by age group (9-11 years, 9.0%; 12-16 years, 11.1%; 17-21 years, 12.9%) and BMI category (range, 9.2% [healthy weight] to 21.9% [severe obesity]). Among those screened, 30.2% had abnormal lipid levels. Compared with youths with a healthy weight, prevalence of an abnormal result was higher among those with overweight (aPR, 1.58; 95% CI, 1.56-1.61), moderate obesity (aPR, 2.16; 95% CI, 2.14-2.19), and severe obesity (aPR, 2.53; 95% CI, 2.50-2.57). Conclusions and Relevance In this cross-sectional study of prevalence of lipid screening among US youths aged 9 to 21 years, approximately 1 in 10 were screened. Among them, abnormal lipid levels were identified in 1 in 3 youths overall and 1 in 2 youths with severe obesity. Health care professionals should consider implementing lipid screening among children aged 9 to 11 years, young adults aged 17 to 21 years, and all youths at high cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
- US Public Health Service Commissioned Corps, Rockville, Maryland.
- Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Public Health Informatics Institute, Task Force for Global Health, Decatur, Georgia.
- Kraushold Consulting, Denver, Colorado.
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
Zitieren
APA
Thompson-Paul, A. M., Kraus, E. M., Porter, R. M., Pierce, S. L., Kompaniyets, L., Sekkarie, A., Goodman, A. B., & Jackson, S. L. (2024). Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records. JAMA Network Open, 7(7), e2421724. https://doi.org/10.1001/jamanetworkopen.2024.21724
Vancouver
Thompson-Paul AM, Kraus EM, Porter RM, Pierce SL, Kompaniyets L, Sekkarie A, et al. Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records. JAMA Network Open. 2024;7(7):e2421724. doi:10.1001/jamanetworkopen.2024.21724
BibTeX
@article{ThompsonPaul2024,
author = {Thompson-Paul, Angela M and Kraus, Emily M and Porter, Renee M and Pierce, Samantha L and Kompaniyets, Lyudmyla and Sekkarie, Ahlia and Goodman, Alyson B and Jackson, Sandra L},
title = {Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {7},
pages = {e2421724},
doi = {10.1001/jamanetworkopen.2024.21724}
}
EUVIMED